Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Cancer Res. 2019 Feb 14;79(7):1353–1368. doi: 10.1158/0008-5472.CAN-18-2383

Figure 7. Inhibition of c-Myc or NF-κB enhances therapeutic efficacy of DOC in AA PCa xenografts.

Figure 7.

A, Clonogenic analysis of LNCaP, DU145, PC-3 and E006AA cells in response to DOC treatment. B, Clonogenic analysis of E006AA cells treated with DOC or DOC in combination with either c-Myc inhibitor or NF-κB inhibitor or AKT activator. C, Immunoblot analysis of CC, caspase-3 cleavage, or PARP cleavage in E006AA hT xenografts treated with DOC or DOC in combination with c-Myc inhibitor or NF-κB inhibitor. D, Caspase-3 activity in E006AA hT xenografts treated with DOC or DOC in combination with c-Myc inhibitor or NF-κB inhibitor. Data represent mean ± SD of 4 independent experiments. Significant differences between means were assessed using analysis of variance (ANOVA) and GraphPad Prism Version 6.0. *p < 0.05 vs respective controls.